PRQR vs. SKYE, GLSI, GOSS, SCPH, RGLS, CRVO, IVA, CAPR, MCRB, and AEON
Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Skye Bioscience (SKYE), Greenwich LifeSciences (GLSI), Gossamer Bio (GOSS), scPharmaceuticals (SCPH), Regulus Therapeutics (RGLS), CervoMed (CRVO), Inventiva (IVA), Capricor Therapeutics (CAPR), Seres Therapeutics (MCRB), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
ProQR Therapeutics (NASDAQ:PRQR) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
ProQR Therapeutics currently has a consensus price target of $3.60, suggesting a potential upside of 79.10%. Skye Bioscience has a consensus price target of $22.50, suggesting a potential upside of 72.81%. Given ProQR Therapeutics' higher possible upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Skye Bioscience.
In the previous week, Skye Bioscience had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Skye Bioscience and 0 mentions for ProQR Therapeutics. Skye Bioscience's average media sentiment score of 0.05 beat ProQR Therapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.
32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ProQR Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500.
ProQR Therapeutics received 323 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 61.95% of users gave ProQR Therapeutics an outperform vote.
ProQR Therapeutics has higher revenue and earnings than Skye Bioscience. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
Skye Bioscience has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -431.65%. Skye Bioscience's return on equity of 0.00% beat ProQR Therapeutics' return on equity.
Summary
ProQR Therapeutics beats Skye Bioscience on 9 of the 16 factors compared between the two stocks.
Get ProQR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProQR Therapeutics Competitors List
Related Companies and Tools
